Momelotinib, a small-molecule oral inhibitor of the JAK1/JAK2 kinases was investigated in the phase 3 MOMENTUM study in patients with anaemic myelofibrosis (ClinicalTrials.gov Identifier: NCT04173494). touchHAEMATOLOGY were delighted to talk with Dr. Srdan Verstovsek (The University of Texas MD Anderson Cancer Center, Houston, TX, USA) to discuss the mechanism of action of momelotinib, the findings […]

Myelofibrosis is a myeloproliferative disorder that leads to severe anaemia and splenomegaly, there is an unmet need for targeting anaemia in the current treatment options for myelofibrosis. In this touchHAEMATOLOGY interview, we spoke with Dr. Srdan Verstovsek (The University of Texas MD Anderson Cancer Center, Houston, TX, USA) around the main challenges of managing myelofibrosis-related […]

María-Victoria Mateos (University of Salamanca, Salamanca, Spain), leading expert in mulitple myeloma, shared her thoughts on the current challenges in CAR-T cell therapy and the strategies being investigated to address them.  CAR-T therapy has introduced a new treatment modality to the triple-class refractory patient population, who had minimal effective treatment options previously. Disclosures: María-Victoria Mateos […]

We were delighted to speak with María-Victoria Mateos (University of Salamanca, Salamanca, Spain) about the recent updates in bispecific monoclonal antibodies for patients with refractory/relapsed multiple myeloma. Disclosures: María-Victoria Mateos discloses the following –  Advisory Board or panel fees from Abbvie, Adaptive, Amgen, Celgene, GlaxoSmithKline, Genentech, Janssen, Oncopeptides, Pfizer, Regeneron, Roche, Sanofi and Takeda. Speaker’s Bureau fees […]

In the burgeoning age of personalized medicine, the treatment of rare anaemias is being transformed from one relying on transfusions and general immunosuppressants to one targeting the underlying disease pathology. Rare anaemias currently experiencing this shift include the autoimmune haemolytic anaemia (AIHA) cold agglutinin disease (CAD), which results from the immune-mediated destruction of erythrocytes. A […]

Multiple myeloma (MM) is a haematological cancer needing continuous, long-term management. Treatment is lifelong and involves numerous clinic visits to receive intravenous or parenteral drugs, and this is burdensome not just for patients but for providers, too. Indeed, the costs associated with treating and managing the condition are among the highest of all malignancies. MM […]

Cold agglutinin disease (CAD) is a rare haemolytic anaemia that causes fatigue, chronic inflammation and thromboembolic complications. Until recently, no therapies have been approved for CAD. Off-label rituximab – a B-cell depleting antibody – induces a short-lived partial response in around half of patients, and adding cytotoxic agents offer further benefit but at the price […]